Nektar Therapeutics
NASDAQ:NKTRBiotechnology
-$1.24 today
- Market cap
- $987.44M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
Volume 0.71M
Average 1.00M
NKTR Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Nektar TherapeuticsNASDAQ: NKTR
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 9.0% from a year ago
Cash & equivalents stood at $39.11M at the end of Q2 FY2026, down 9.0% from a year earlier and down 70.3% from the prior quarter. Over 3 fiscal years it compounded at -44.5% a year.
Context
- Cash & equivalents amounted to 3.6% of total assets at the end of Q2 FY2026, down 17.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -9.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 15.12M USD
- Year-over-year change
- -65.8%
- 4-year CAGR
- -12.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.12M | -65.8% |
| FY2024 | 2024-12-31 | 44.25M | +25.4% |
| FY2023 | 2023-12-31 | 35.28M | -60.0% |
| FY2022 | 2022-12-31 | 88.23M | +249.9% |
| FY2021 | 2021-12-31 | 25.22M | — |
Cash & Equivalents vs competitors
How NKTR compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -9.0% is the 6th highest of 11, against a peer median of -9.9%.
- Cash & equivalents amounts to 3.6% of total assets for NKTR, versus a peer median of 36.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $452.68M USD | -5.1% | +5.1% | 42.2% | |
| Mar 2026 | €301.65M EUR | +24.2% | +32.5% | 55.5% | |
| Jun 2026 | $150M USD | -39.5% | +2.5% | 16.2% | |
| Mar 2026 | $115.24M USD | +39.8% | +11.8% | 43.3% | |
| Mar 2026 | $66.52M USD | -54.3% | -19.3% | 30.5% | |
| Jun 2026 | $44.66M USD | +0.5% | +0.1% | 6.2% | |
| Mar 2026 | $40.1M USD | +702.2% | -29.7% | 15.8% | |
| Jun 2026 | $39.11M USD | -9.0% | -44.5% | 3.6% | |
| Dec 2025 | €28.08M EUR | -57.7% | -30.7% | 44.8% | |
| Dec 2025 | $23.79M USD | -60.9% | -17.8% | 69.1% | |
| Mar 2026 | $12.44M USD | -14.7% | +101.6% | 8.5% | |
| Peer median (excluding NKTR) | — | -9.9% | +1.3% | 36.4% | |
Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25.22M | 88.23M | 35.28M | 44.25M | 15.12M |
| Short-term Investments | 708.74M | 416.75M | 268.34M | 210.97M | 230.64M |
| Net Receivables | 22.49M | 8.4M | 2.25M | 1.61M | 1.78M |
| Inventory | 15.8M | 19.2M | 16.1M | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 795.58M | 545.97M | 330.7M | 261.29M | 266.27M |
| Property, Plant & Equipment (Net) | 177.54M | 85.89M | 36.86M | 11.82M | 5M |
| Goodwill | 76.5M | 76.5M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 64.83M | 0 | 25.83M | 26.09M | 3.49M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.74M | 2.25M | 4.64M | 4.65M | 5.65M |
| Total Non-current Assets | 321.61M | 164.63M | 67.33M | 42.56M | 14.14M |
| Total Assets | 1.12B | 710.6M | 398.03M | 303.85M | 280.41M |
| Account Payables | 9.75M | 12.98M | 9.85M | 11.56M | 10.77M |
| Short-term Debt | 0 | 0 | 0 | 0 | 20.5M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 15.74M | 9.58M | 5.55M | 5.55M | 22.27M |
| Total Current Liabilities | 85.2M | 68.2M | 51.27M | 61.4M | 53.54M |
| Long-term Debt | 0 | 0 | 0 | 0 | 63.16M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 226.75M | 162.93M | 117.26M | 99.02M | 8.63M |
| Total Non-current Liabilities | 352.48M | 275.76M | 215.78M | 181.71M | 137.04M |
| Total Liabilities | 437.68M | 343.96M | 267.05M | 243.11M | 190.57M |
| Common Stock | 19K | 19K | 19K | 19K | 2K |
| Retained Earnings | (2.83B) | (3.2B) | (3.48B) | (3.6B) | (3.76B) |
| Accumulated OCI | (4.16M) | (6.91M) | 80K | 61K | 17K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 679.51M | 366.64M | 130.99M | 60.74M | 89.83M |
| Total Debt | 143.18M | 131.5M | 117.78M | 102.56M | 148.91M |
| Net Debt | 117.96M | 43.27M | 82.5M | 58.31M | 133.79M |
Nektar Therapeutics
NASDAQ:NKTR
Intrinsic Alpha fair value
Locked
Current Price
$34.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.